414 related articles for article (PubMed ID: 26039245)
1. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
3. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
5. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
6. Association between androgen receptor status and prognosis in triple negative breast cancer.
Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
[TBL] [Abstract][Full Text] [Related]
7. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
Pan Y; Yuan Y; Liu G; Wei Y
PLoS One; 2017; 12(2):e0172324. PubMed ID: 28235003
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA
Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116
[TBL] [Abstract][Full Text] [Related]
9. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status.
Shen S; Sun Q; Liang Z; Cui X; Ren X; Chen H; Zhang X; Zhou Y
PLoS One; 2014; 9(6):e100664. PubMed ID: 24945253
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes.
DiNome ML; Orozco JIJ; Matsuba C; Manughian-Peter AO; Ensenyat-Mendez M; Chang SC; Jalas JR; Salomon MP; Marzese DM
Ann Surg Oncol; 2019 Oct; 26(10):3344-3353. PubMed ID: 31342401
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.
Adamo B; Ricciardi GRR; Ieni A; Franchina T; Fazzari C; Sanò MV; Angelico G; Michele C; Tuccari G; Adamo V
Oncotarget; 2017 Sep; 8(44):76974-76986. PubMed ID: 29100362
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
13. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters.
Hashmi AA; Hashmi KA; Irfan M; Khan SM; Edhi MM; Ali JP; Hashmi SK; Asif H; Faridi N; Khan A
BMC Res Notes; 2019 Sep; 12(1):605. PubMed ID: 31547858
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
[TBL] [Abstract][Full Text] [Related]
15. Preserved Axin expression is associated with an aggressive phenotype in invasive breast carcinomas.
Irini T; Paraskevi A; Ioanna G; Christos P; Lydia N
APMIS; 2013 Sep; 121(9):797-805. PubMed ID: 23278310
[TBL] [Abstract][Full Text] [Related]
16. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
17. Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice.
Losurdo A; De Sanctis R; Fernandes B; Torrisi R; Masci G; Agostinetto E; Gatzemeier W; Errico V; Testori A; Tinterri C; Roncalli M; Santoro A
Sci Rep; 2020 Nov; 10(1):20100. PubMed ID: 33208857
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
